Joseph Connell

Have a technology for on-demand manufacturing of vaccines or therapeutics? EverGlade Consulting can help you obtain BARDA funding to advance your critical work. #innovation #health #biotechnology #scienceandtechnology #research #science #publichealth #covid19

2

In a significant win for patentees, the Federal Circuit clarified the scope of obviousness-type double patenting, holding that a first-filed, first-issued, later-expiring patent cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority claim. This is a big deal for patent prosecutors because often the first patent in a patent family has the longest prosecution and therefore the most patent term adjustment (PTA). This decision allays previous concerns that the PTA of first family members was at risk for obviousness-type double patenting based upon later family members issued without PTA that arose following the Cellect decision last year. Read more in the article I wrote with Jeff Schmidt, PhD, MBA, JD and Karen G. Potter on the MoFo Life Science Blog. https://lnkd.in/gf6vTN4g

15

⭐⭐⭐⭐⭐ Plus Therapeutics of Austin TX is winning the battle against the deadliest cancers. 😀 🤩 😎 ☺️Major catalysts ahead in 2025 are more MM$ grant approvals, MM$ CNS testing revenues, continued pipeline progress & more great clinical results as dosage increases, new medical device application to be submitted to FDA in next 6 months for Rhenium 188 lipospheres to treat liver cancer (huge deal as medical devices are approved much quicker by the FDA), and Wow! what a pipeline. M&A has targeted several radiotherapy peers that treat cancer, but PSTV's biotech is truly STELLAR thanks to incredible efficacy, safety, no/minimal damage to surrounding tissue, the delivery system, and great results vs. the deadliest cancers. PSTV is a no brainer five star BUY BUY BUY here with more great news ahead or M&A ahead. Look at $5.1MM grant revenue YTD and the recent INSIDER BUYING. PSTV has three buy ratings from Analysts, a $14.50 one-year price target, and has just reached an ideal buy, buy, buy price. 😀 🤩 😎 ☺️

1

3 Comments

VCLink's Daily Round Report (Part 1) 1. David Hirsch's Alpha-9 Oncology, a radiopharmaceuticals company, raised $175 million in its Series C from Lightspeed and Ascenta Capital. General Catalyst, a16z Bio + Health, and RA Capital Management also participated in the round. https://lnkd.in/eaWRT4PB 2. Simon Kalouche's Nimble, a fulfillment technology provider, has raised $106 million in its Series C from FedEx. Cedar Pine also participated in the round. https://lnkd.in/eeeYw7Zi 3. Joanne Smith-Farrell's Be Biopharma, a biotech company, has raised $82 million to advance its pipeline programs, BE-101 and BE-102, for improving treatment outcomes for Hemophilia B. ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures, Inc. participated in the round. https://lnkd.in/enpZ6EEM 4. Richie Serna's Finix, a SF-based payments company, has raised $75 million in its Series C from Acrew Capital. Leap and Lightspeed Capital also participated in the round. https://lnkd.in/e3wDMstK 5. Infinitus Systems, Inc., a healthcare AI automation company, has raised $51.5 million in its Series C from Andreessen Horowitz to optimize claim processing and streamline payor systems. https://lnkd.in/eQr4RQAR 6. Jit Bhattacharya's BasiGo, a Kenya-based electric bus startup, has raised $41.5 million in Series A equity and debt funding to grow its fleet of electric buses and expand operations in East Africa. Africa50, British International Investment, and U.S. Development Finance Corporation led the round. https://lnkd.in/e6B9XcNp 7. Srinivas Njay and Bruce Kim's interface.ai, a customer automation platform, has raised $30 million to advance its AI-driven services for banks and credit unions. The round was led by Avataar Venture Partners. https://lnkd.in/evn9Vr2r 8. Granola, an AI-powered meeting notepad app, has secured $20 million in a funding round led by Spark Capital. The funds will be used to expand the team and develop new functionalities for teams and enterprise users. https://lnkd.in/e3UtEn-2

11

Abbisko Therapeutics announced a positive profit alert for the first half of 2024. On July 10, 2024, Abbisko Therapeutics (Hong Kong Stock Exchange code: 02256) announced a positive profit alert. The company estimates its total revenue for the first half of 2024 to be approximately RMB497 million, marking a significant turnaround from deficits to profits. The profit during this period is estimated to be between RMB200 million and 220 million, representing the company's first half-yearly profit achievement.   According to the preliminary review of the company’s unaudited management accounts for the six months ended June 30, 2024, the total revenue of the company for the six months ended June 30, 2024, is expected to be approximately RMB497 million, representing an increase of RMB478 million from approximately RMB19 million for the six months ended June 30, 2023; and the company is expected to record a profit for the period within the range of RMB200 million to RMB220 million for the six months ended June 30, 2024, compared to a loss for the period of approximately RMB209 million for the six months ended June 30, 2023. Apart from the improved cost control through enhanced business operation efficiency, the anticipated increase in total revenue and turnaround from loss to profit was also mainly attributable to the out-licensing agreement for pimicotinib (ABSK021) and the upfront payment of US$70 million (RMB497 million) with MERCK, which contributed significantly to the revenue for the six months ended June 30, 2024.

9